The two organizations join forces to improve global access to radiopharmaceutical therapy, with the Oncidium foundation aiming to provide 2,000 doses in five years through the initiative
, /PRNewswire/ — SHINE Technologies, a next-generation fusion company, today announced a collaboration with the Oncidium foundation, a non-profit organization dedicated to improving global access to radiopharmaceuticals. As part of the collaboration, SHINE is donating doses of Ilumira, its non-carrier added lutetium-177 chloride, to cancer patients in under-resourced countries in need of radiopharmaceutical therapy.
SHINE donates cancer therapy doses to underserved patients via Oncidium foundation’s RLT-Connect
The doses will be made available through the Oncidium foundation’s RLT-Connect platform, which is designed to connect healthcare professionals seeking radiopharmaceutical therapy for their patients and radioisotope suppliers willing to donate doses to make this life-saving treatment accessible to those in need. The Oncidium foundation’s initiative aims to provide 2,000 doses of radiopharmaceutical therapy in five years.
“Partnering with SHINE through …